decisionhealth Newsletters, Coder Pink Sheets - 2005 Issue 7 (July)
Competitive acquisition program: Will it help with costs for bladder cancer drugs?
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS competitive acquisition proposal for physician-administered Part B drugs and why it drew attention from urology groups. It discusses how the proposal relates to Medicare drug purchasing, vendor selection, and physician billing, and it places the issue in the context of bladder cancer and interstitial cystitis treatment drugs. The piece is relevant to coding, reimbursement, and practice management audiences monitoring Medicare drug payment policy.
Why This Topic Matters
The article helps readers understand a Medicare payment policy change that could affect how physician-administered drugs are obtained, billed, and reimbursed in urology practices. It is especially relevant for practices managing drug acquisition costs and monitoring federal payment policy changes.
What You Will Learn
- How a CMS competitive acquisition proposal is framed for physician-administered drugs
- How the proposal relates to Medicare Part B drug purchasing and billing
- Why urology stakeholders raised concerns about drug acquisition costs and access
- Which general urology drug categories were highlighted in the discussion
Who Should Read This
- Urologists
- Urology practice managers
- Medical coders
- Billing staff
- Revenue cycle professionals
- Healthcare policy analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com